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Assessment of Gender Representation in Clinical Trials Leading
to FDA Approval for Oncology Therapeutics Between 2014 and
2019: A Systematic Review-Based Cohort Study
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BACKGROUND: Ensuring representative data accrual in clinical trials is important to safeguard the generalizability of results and to
minimize disparities in care. This study’s goal was to evaluate differences in gender representation in trials leading to US Food and
Drug Administration (FDA) cancer drug approvals. METHODS: An observational study was conducted from January 2014 to April 2019
using PubMed and the National Institutes of Health trials registry for primary trial reports. The National Cancer Institute’s Surveillance,
Epidemiology, and End Results program and US Census were consulted for national cancer incidence. The outcome was an enrollment
incidence disparity (EID), which was calculated as the difference between male and female trial enrollment and national incidence, with
positive values representing male overrepresentation. RESULTS: There were 149 clinical trials with 59,988 participants—60.3% and 39.7%
were male and female, respectively—leading to 127 oncology drug approvals. The US incidence rates were 55.4% for men versus 44.6%
for women. Gender representation varied by specific tumor type. Most notably, women were underrepresented in thyroid cancer (EID,
+27.4%), whereas men were underrepresented in soft tissue cancer (EID, –26.1%). Overall, women were underrepresented when compared with expected incidence (EID, +4.9%; 42% of trials). CONCLUSIONS: For many specific tumor types, women are underrepresented
in clinical trials leading to FDA oncology drug approvals. It is critical to better align clinical trial cohort demographics and the populations
to which these data will be extrapolated. Cancer 2021;0:1-7. © 2021 American Cancer Society.
LAY SUMMARY:
• This study assesses whether gender disparities exist in clinical trials leading to US Food and Drug Administration (FDA) cancer drug
approvals. From January 2014 to April 2019, 149 clinical trials leading to FDA oncology drug approvals showed 60.3% and 39.7% of the
enrollees were male and female, respectively.
• Gender representation varied by specific tumor when compared with the expected incidence rate of cancer in the United States,
although women were more often underrepresented.
• Increased efforts are needed with regard to ensuring equitable representation in oncology clinical trials.
KEYWORDS: clinical trials, drug approval, health care disparities, medical oncology, sexism.

INTRODUCTION
Gender disparities in health care have influenced processes for appropriate diagnoses and treatment of many health
conditions.1 Among patients with cancer, these epidemiological variations have driven advancements to alleviate
gender-specific differences in cancer susceptibility and mortality.2,3 Clinical trials are essential for the development
of novel cancer drug treatments and can benefit the medical community.4 As a result of the evidence that women
were underrepresented in important clinical trials, in 1993, the US National Institutes of Health (NIH) issued the
Revitalization Act: a guideline for the evaluation of gender and minority differences in clinical trials for the full range
of patients using the therapy.5,6,7 In 2016, the European Association of Science Editors published the influential
Sex and Gender Equity in Research guidelines to integrate sex and gender reporting into articles.8 Currently, cancer
clinical trials incorporate sex differences for a better understanding of the efficacy and toxicity of chemotherapeutics,
as well as the roles of genetics and sex hormones.9 However, trial populations may not always represent the population
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that they are trying to emulate. It has been shown in
several studies, in both oncology and nononcology clinical trial settings, that women may be underrepresented
in clinical trials.10-13 Although some reports refute this
claim and a plethora of barriers exist to clinical trial
participation and enrollment, there are known differences in the clinical outcome of medications, such as
adverse drug reactions, which may be missed in underrepresented trials.14-16 Physiologic variations may affect
the pharmacokinetics and pharmacodynamics of these
oncology drugs, so these differences need to be assessed
for clinical relevance.11 It is critical that trial data from
men and women are not only available, but that they
also effectively represent the treated population when
decisions on safety, efficacy, side effects, and dosing of
therapeutic agents are being made.11
Other studies have shown the existence of racial
and age disparities in oncology clinical trials, but are
less robust in assessing gender variation.17,18 Mendis
et al recently showed a slight female underrepresentation in hematological trials and a significant underrepresentation in solid organ malignancies using the
International Agency for Research on Cancer and odds
ratios for female trial enrollment.13 The purpose of
this study was to further clarify whether there is truly a
gender disparity in clinical trials leading to cancer drug
approvals using US Food and Drug Administration
(FDA)-approved clinical trials from January 2014 to
April 2019 by calculating enrollment incidence disparity (EID) using the National Cancer Institute (NCI)
Surveillance, Epidemiology, and End Results (SEER)
program database. We hypothesized that many registration trials were not representative of the cancer patient
population in the United States with respect to the age-
adjusted incidence of the targeted cancer.
MATERIALS AND METHODS
Study Cohort

This study was exempt from institutional review board
approval based on the public and deidentified nature
of the work, following the standards of the Helsinki
Declaration.
The FDA systematically identified and listed all
oncology-specific drug approvals from the FDA drug
archives database from January 2006 to April 2019.19
We isolated those between January 2014 and April
2019 for our study. Based on these approvals, we identified the trials that formed the evidentiary base for the
approval using FDA reviews, PubMed, and the NIH
2

trials registry (ClinicalTrials.gov).19,20 Notably, this
approach to study identification has previously been
used in other analyses examining disparities in clinical
trials enrollment.17 Among identified FDA approvals,
we excluded those that were for male-or female-specific
cancers (eg, prostate cancer or ovarian cancer), did not
provide gender information for enrollees, could not be
matched to cancers listed in the NCI SEER program
database, had FDA drug-approval dates outside of the
defined range, or did not fall under solid tumor or
hematology-oncology categories. When multiple trials
supported an FDA drug approval, each unique trial was
included in the analysis.
To compare clinical trial demographics to national
cancer statistics, the NCI SEER program database was
consulted for specific cancer age-adjusted incidence rates
per 100,000 by gender from 2014 to 2016.21 Because the
database did not include incidence rates from 2017 to
2019, they were estimated using 2016 SEER age-adjusted
incidence rate values. Those values were correlated to the
year’s US Census population estimates to determine the
approximate rate of increase or decrease in cancer incidence by gender.22
Analysis and Outcome Measures

First, each clinical trial was matched to the appropriate cancer category listed in the SEER program database based on the targeted organ and cancer type from
histologic findings. We then analyzed the clinical trial
data and identified the male and female enrollment percentages overall, as well as by specific cancer type. The
total numbers of male and female trial participants for
each cancer category were combined. Subsequently, the
male and female enrollment percentage was calculated
for each cancer type based on the combined value, allowing for a weighted average. For national cancer incidence between 2014 and 2019, the male and female
age-adjusted rate per 100,000 was combined for each
cancer category, and gender-specific incidence rate percentages were calculated.
We compared male and female clinical trial enrollment with national incidence data by calculating the
EID. The EID was calculated as the difference between
the male and female clinical trial enrollment and national
incidence percentages. The EID values were calculated
for the overall cancer population, as well as by specific
cancer type. Positive values indicate an overrepresentation
in males in clinical trials when compared with incidence,
whereas negative values indicate an underrepresentation
of males.
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Figure 1. Breakdown of reviewed US Food and Drug Administration (FDA) approvals, exclusion criteria and number of trials used for
gender analyses. The FDA approved 72 drugs in 127 distinct approvals based on 149 clinical trials included in this study. NCI indicates
National Cancer Institute; SEER, Surveillance, Epidemiology, and End Results.

RESULTS
Baseline Approval and Trial Characteristics

The FDA approved 72 drugs in 127 distinct approvals based on 149 clinical trials included in this study
(Supporting Table 1). A total of 261 trials were identified
from our initial search. Based on exclusion criteria, 112
trials were excluded, leaving 149 included studies (Fig. 1).
Notably, among the 112 trial excluded, 23 studies
(20.5%) were excluded as gender details were not provided. The characteristics of the 149 clinical trials are
shown in Table 1 and separated by year in Supporting
Table 1. Most approvals were completed in 2017 (n = 40,
26.8%) and 2018 (n = 39, 26.2%). The majority of
approvals were for lung and bronchus cancer (n = 34,
22.8%), followed by leukemia (n = 33, 22.1%), melanoma (n = 16, 10.7%), and non-Hodgkin lymphoma
(n = 16, 10.7%). The trials were mostly multiple arm
(n = 115, 77.2%) and phase 3 (n = 77, 51.7%) with between 100 and 500 participants enrolled (n = 84, 56.4%).
Gender Disparity Between Clinical Trials and the
US Population by Cancer Type and Overall

A total of 59,988 patients were enrolled in the 149 included clinical trials. We assessed gender representation in
clinical trials and national incidence rates across 14 specific cancer types (Table 2). Compared with population-
based estimates, disparities in gender representation
varied depending on specific cancer subtype. Most notably, women were underrepresented in thyroid and liver/
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intrahepatic bile duct cancers, whereas men were underrepresented in soft tissue and bladder cancers.
Using an assessment of EID indicative of disparities
between trial enrollment and population-based incidence
for specific cancer types (Table 2), 8 out of 14 cancer sites
(57%) showed an overrepresentation of men. The largest disparities were seen in thyroid (men overrepresented
EID, +27.4), soft tissue (men underrepresented EID,
–26.1), bladder (men underrepresented EID, –10.8), and
liver/intrahepatic bile duct (men overrepresented EID,
+9.9) cancers.
Overall, 60.3% (n = 36,193) of the enrollees were
male and 39.7% (n = 23,795) were female. Across all cancer types including sex-specific cancers, US population-
based data show that men account for 55.4% of incident
cancer diagnoses (age-adjusted rate per 100,000 = 762.78)
versus 44.6% for women (age-adjusted rate per 100,000
= 614.46; Fig. 2). The EID showed an overrepresentation
of men (EID, +4.9%; 42% of trials; Table 2).
DISCUSSION
In this study of clinical trials leading to approvals of oncology drugs by the FDA, we found that gender representation varied by specific cancer type with women being
more often underrepresented when compared with national cancer incidence. To our knowledge, despite FDA
guidelines and strategies to try to alleviate the differences
in gender representation in oncology clinical trials, this
3
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TABLE 1. Characteristics of US Food and Drug
Administration Approvals/Trials for Hematology/
Oncology, January 2014 to April 2019
Characteristics
Year of approval
2014
2015
2016
2017
2018
2019
Specific disease for approval—
all cancer sites combined
Solid tumor oncology
Lung and bronchus
Melanoma
Urinary bladder
Kidney and renal pelvis
Colorectal
Stomach
Liver and intrahepatic bile duct
Thyroid
Soft tissue including heart
Pancreas
Hematology
Leukemia
Non-Hodgkin lymphoma
Multiple myeloma
Hodgkin lymphoma
Trial characteristics
Arms on trial
Single
Multiple
Unknown
Phase of trial
1
2
3
4
1/2
2/3
Unknown
Size of trial (number enrolled)
<100
100-500
>500

No. (%)
17 (11.4)
31 (20.8)
16 (10.7)
40 (26.8)
39 (26.2)
6 (4.0)
1 (0.7)
34 (22.8)
16 (10.7)
7 (4.7)
6 (4.0)
6 (4.0)
5 (3.4)
5 (3.4)
2 (1.3)
2 (1.3)
1 (0.7)
33 (22.1)
16 (10.7)
11 (7.4)
4 (2.7)

33 (22.1)
115 (77.2)
1 (0.7)
10 (6.7)
33 (22.1)
77 (51.7)
2 (1.3)
21 (14.1)
5 (3.4)
1 (0.7)
20 (13.4)
84 (56.4)
45 (30.2)

is the first study to assess gender representation in these
trials.11 Guidelines in effect as of June 2015 require applicants to “explain how relevant biological variables, such
as sex, are factored into research designs and analyses.”
Strong justification from the scientific literature, preliminary data, or other relevant consideration is required from
researchers planning to study only one sex.23 The data in
this study suggest that these current guidelines and strategies have proven inadequate to address existing disparities.
Gender disparities in oncology clinical trials continue to be a concern with women more often underrepresented when compared with US incidence cancer
rates. Additionally, similar trends are noted with EID
in this study. Multiple studies are concordant with our
findings and have emphasized the importance of gender
4

representation in clinical trials.11 Even after the US NIH
Revitalization Act of 1993 was issued to require research
on gender differences in clinical trials, the US Government
Accountability Office released multiple statements further
recommending improved study design to allow for results
analysis by gender. Those reports recommended strategies like peer-reviewed publications and strong journal
policies to monitor compliance, but unfortunately these
policies have not resulted in significant increases in either
accrual of women or reporting by sex.7 Despite women
being the major consumers of health care and prescription drugs and the primary decision-makers about health
care for their families, this problem still persists.24
Across cancer subsets, the EID results varied with
some underrepresentation of males and some of females.
In particular, soft tissue malignancies and thyroid cancer
show the greatest degree of gender incidence variation
compared with other cancer subsets with male overrepresentation for thyroid (EID, +27.4) and female overrepresentation for soft tissue cancer (EID, –26.1). Postulation
as to the causes underlying identified gender discrepancies in clinical trial enrollment is beyond the scope of the
analysis undertaken. However, potential factors include
trial inclusion/exclusion criteria, such as restriction to
specific interventions, concurrent diagnoses or comorbidities, contraindicated medications, and funding;
trial-related burdens including travel distance, additional
out-
of-
pocket expenses, caregiver burdens, and family
responsibilities that may differentially affect women; or
potentially, though unproven, decreased willingness to go
to treatment or participate.25,26
Other criteria such as the presence of industry funding, performance status, changing gender representation
over time, and mortality were chosen to be excluded from
this study, although some of these have been assessed
in other studies.17,18 Mortality was not assessed as incidence was deemed a better representation of clinical trial
demographics and studies. Understanding any gender
disparities that exist within oncology clinical trials is critical to continuing to address these concerns in medicine,
especially with the number of cancer cases expected to
increase by >20% and an increasing number of clinical
trials every year.27 The goal is to ensure that oncologic advancements resulting from these trials are applicable to all
people with cancer, regardless of gender. However, given
these results and others showing disparities based on age
and race, it is clear that further work is required to ensure
that trials informing oncology drug approvals are generalizable to the patient populations in which these agents
will be used.17,18 As an initial step, actions could include
Cancer  
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TABLE 2. Relative Differences in Male and Female Enrollment in Clinical Trials and Incidence Rate by Specific
Cancer Type
Clinical Trials

Colon and rectum
Digestive—stomach
Hodgkin lymphoma
Kidney cancer and renal pelvis
Leukemia
Liver and intrahepatic bile duct
Lung and bronchus
Melanoma of the skin
Myeloma
Non-Hodgkin lymphoma
Pancreas
Soft tissue including heart
Thyroid
Urinary bladder
Overall

Population-Based Incidence

Male (%)

Female (%)

Male (%)

Female (%)

EID

60.3
72.1
57.0
74.5
58.7
84.0
59.1
56.4
56.2
52.9
56.8
33.2
53.3
69.2
60.3

39.7
27.9
43.0
25.5
41.3
16.0
40.9
43.6
43.8
47.1
43.2
66.8
46.7
30.8
39.7

56.4
64.4
55.4
67.1
62.7
74.1
55.8
62.1
60.6
59.3
56.0
59.3
25.8
80.0
55.4

43.6
35.6
44.6
32.9
37.3
25.9
44.2
37.9
39.4
40.7
44.0
40.7
74.2
20.0
44.6

3.9
7.7
1.6
7.4
−4.0
9.9
3.2
−5.7
−4.3
−6.4
0.8
−26.1
27.4
−10.8
4.9

Enrollment incidence disparity (EID) shows the gender disparity between clinical trials and US population by specific cancer type. Positive EID values indicate an
overrepresentation of males (green color) in clinical trials when compared with incidence, whereas negative values indicate an underrepresentation of males (red
color). Darker colors correlate to a stronger variation between the trials and the population.
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Figure 2. Comparison of male and female oncology clinical trial enrollment with US cancer incidence from 2014 to 2019.

implementing best practice recommendations, helping
to establish gender-specific evidence-based guidance, ensuring analysis and reporting by gender, and encouraging
further patient and researcher education.
Limitations

Several limitations should be considered with respect to
this study. Trials were excluded that did not report the
gender distribution of enrollees. Therefore, this analysis
may either under-or overestimate the gender disparity in
these oncology trials. We only examined studies leading
to FDA drug approvals. Thus, these results cannot necessarily be extrapolated to phase 1 or 2 trials or those that
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did not lead to drug approval. Additionally, SEER disease-
specific estimates for incidence may be a function of how
disease-specific estimates were weighted and adjusted for
using census data and thus may account for differences in
estimations available in the current literature. Because the
SEER program database used did not include incidence
rates from 2017 to 2019, these were estimated using 2016
SEER age-adjusted incidence-rate values. We extrapolated
our analysis to US Census population estimates, but did
not adjust for global trial participation or changing mortality rates over time. Additionally, we combined the age-
adjusted incidence rate per 100,000 for the years 2014
to 2019 for each cancer category and did not account for
5
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change over time. We considered using a generalized least
squares regression model with a recency decay factor but
because the sample sizes were large enough over 5 years,
we chose to use a pure average and did not account for
variances by year. Furthermore, in the global assessment
of cancer incidence—because of limitations in the SEER
data set—we were unable to derive an estimate exclusive
of sex-specific cancers; thus, these were included in the
total incidence. Also, as the world population gender distribution is 1.01:1 male to female, some trials included
large numbers of individuals from a single country outside the United States.28 Therefore, we cannot assume the
oncology demographics between males and females are
consistent in every country because of differing treatment
and screening practices and access to health care. It is
worth noting that some clinical trials showed conflicting
reports on how many men versus women were included
in the trial depending on the source of the information
(eg, PubMed vs. FDA vs. referenced study). Overall, the
causes of gender disparity are complex, and the impact
of biological, environmental, social, and financial factors
should be acknowledged. Whether these potential disparities result in discrepant clinical outcomes remains to be
seen and should be analyzed in future studies.
Overall, we found evidence of gender disparities in
oncology clinical trials leading to drug approvals, with
women more often underrepresented when compared
with the US incidence cancer rates for specific tumor
types. This offers an opportunity for additional targeted
research and intervention for specific cancers, including
thyroid and liver/intrahepatic bile duct cancers. Increased
efforts are needed with regards to improving both female
representation overall and equitable representation by individual cancer subset in oncology clinical trials. Future
studies are needed to better understand the factors influencing the differences observed in this study and how best
to move forward in addressing these differences with the
goal of equal representation in modern cancer research.
With the growing cancer burden in the aging population,
eliminating the potential inequalities highlighted in this
study is crucial to ensure the generalizability of future
clinical trial results and optimal patient care.
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